Global Antibody Partnering Terms and Agreements 2016-2023
The Global Antibody Partnering Terms and Agreements 2016 - 2023 report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
The Global Antibody Partnering Terms and Agreements 2016 to 2023 report provides comprehensive understanding and unprecedented access to the antibody partnering deals and agreements entered into by the worlds leading healthcare companies.
The report provides a detailed understanding and analysis of how and why companies enter antibody partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors antibody technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
This report provides details of the latest antibody agreements announced in the healthcare sectors, covering:
- Antibodies
- Antibody-drug conjugates
- Monoclonal antibodies
- Murine mAb
- Chimeric mAb
- Humanized mAb
- Human aAb
- Bispecific antibodies
- Polyclonal antibodies
Understanding the flexibility of a prospective partner’s negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered – contract documents provide this insight where press releases do not.
This report contains over 1,900 links to online copies of actual antibody deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners. Contract documents provide the answers to numerous questions about a prospective partner’s flexibility on a wide range of important issues, many of which will have a significant impact on each party’s ability to derive value from the deal.
The initial chapters of this report provide an orientation of antibody dealmaking and business activities. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in antibody dealmaking since 2016, including details of average headline, upfront, milestone and royalty terms.
Chapter 3 provides a review of the leading antibody deals since 2016. Deals are listed by headline value, signed by big pharma, most active antibody dealmaking companies. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive listing of the top 25 most active companies in antibody dealmaking with a brief summary followed by a comprehensive listing of antibody deals, as well as contract documents available in the public domain. Where available, each deal title links via Weblink to an online version of the actual contract document, providing easy access to each contract document on demand.
Chapter 5 provides a comprehensive and detailed review of antibody partnering deals signed and announced since Jan 2016, where a contract document is available in the public domain. The chapter is organized by company A-Z, deal type (collaborative R&D, co-promotion, licensing etc), and specific therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Chapter 6 provides a comprehensive and detailed review of antibody partnering deals signed and announced since Jan 2016. The chapter is organized by specific antibody technology type in focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
In addition, a comprehensive appendix is provided organized by antibody partnering company A-Z, deal type definitions and antibody partnering agreements example. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The report also includes numerous tables and figures that illustrate the trends and activities in antibody partnering and dealmaking since 2016.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of antibody technologies and products.
Key benefits
Global Antibody Partnering Terms and Agreements 2016 to 2023 provides the reader with the following key benefits:
- In-depth understanding of antibody deal trends since 2016
- Access to headline, upfront, milestone and royalty data
- Detailed access to actual antibody contracts enter into by the leading 25 bigpharma companies
- Insight into the terms included in a antibody agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Report scope
Global Antibody Partnering Terms and Agreements 2016 to 2023 is intended to provide the reader with an in-depth understanding and access to antibody trends and structure of deals entered into by leading companies worldwide.
Global Antibody Partnering Terms and Agreements 2016 to 2023 includes:
- Trends in antibody dealmaking in the biopharma industry since 2016
- Access to headline, upfront, milestone and royalty data
- Access to over 1,900 antibody online deal records
- The leading antibody deals by value since 2016
- Most active antibody dealmakers since 2016
- The leading antibody partnering resources
In Global Antibody Partnering Terms and Agreements 2016 to 2023, the available contracts are listed by:
- Company A-Z
- Headline value
- Stage of development at signing
- Deal component type
- Specific therapy target
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
The Global Antibody Partnering Terms and Agreements 2016 to 2023 report provides comprehensive access to available deals and contract documents for over 1,900 antibody deals. Analyzing actual contract agreements allows assessment of the following:
- What are the precise antibody rights granted or optioned?
- What is actually granted by the agreement to the partner company?
- What exclusivity is granted?
- What is the payment structure for the deal?
- How are sales and payments audited?
- What is the deal term?
- How are the key terms of the agreement defined?
- How are IPRs handled and owned?
- Who is responsible for commercialization?
- Who is responsible for development, supply, and manufacture?
- How is confidentiality and publication managed?
- How are disputes to be resolved?
- Under what conditions can the deal be terminated?
- What happens when there is a change of ownership?
- What sublicensing and subcontracting provisions have been agreed?
- Which boilerplate clauses does the company insist upon?
- Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
- Which jurisdiction does the company insist upon for agreement law?
Global Antibody Partnering Terms and Agreements 2016-2023 provides the reader with the following key benefits:
- In-depth understanding of antibody deal trends since 2016
- Access to headline, upfront, milestone and royalty data
- Comprehensive access to over 1,900 actual antibody deals entered into by the world’s biopharma companies, together with contract documents if available
- Detailed access to actual antibody contracts enter into by the leading companies
- Identify leading antibody deals by value since 2016
- Identify the most active antibody dealmakers since 2016
- Insight into the terms included in an antibody agreement, together with real world clause examples
- Understand the key deal terms companies have agreed in previous deals
- Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Executive Summary
Chapter 1 – Introduction
Chapter 2 – Trends in antibody dealmaking
2.1. Introduction
2.2. Antibody partnering over the years
2.3. Most active antibody dealmakers
2.4. Antibody partnering by deal type
2.5. Antibody partnering by therapy area
2.6. Deal terms for antibody partnering
2.6.1 Antibody partnering headline values
2.6.2 Antibody deal upfront payments
2.6.3 Antibody deal milestone payments
2.6.4 Antibody royalty rates
Chapter 3 – Leading antibody deals
3.1. Introduction
3.2. Top antibody deals by value
Chapter 4 – Most active antibody dealmakers
4.1. Introduction
4.2. Most active antibody dealmakers
4.3. Most active antibody partnering company profiles
Chapter 5 – Antibody contracts dealmaking directory
5.1. Introduction
5.2. Antibody contracts dealmaking directory
Chapter 6 – Antibody dealmaking by technology type
Appendices
Appendix 1 – Antibody deals by company A-Z
Appendix 2 – Antibody deals by stage of development
Discovery
Preclinical
Phase I
Phase II
Phase III
Regulatory
Marketed
Formulation
Appendix 3 – Antibody deals by deal type
Asset purchase
Assignment
Bigpharma outlicensing
Co-development
Collaborative R&D
Co-market
Co-promotion
CRADA
Cross-licensing
Development
Distribution
Equity purchase
Evaluation
Grant
Joint venture
Licensing
Loan
Manufacturing
Marketing
Material transfer
Option
Promotion
Research
Settlement
Spin out
Sub-license
Supply
Technology transfer
Termination
Appendix 4 – Antibody deals by therapy area
Cardiovascular
Central Nervous System
Dental
Dermatology
Gastrointestinal
Hematology
Hospital care
Immunology
Infectives
Metabolic
Musculoskeletal
Obstetrics
Oncology
Ophthalmics
Orphan disease
Pediatrics
Psychiatry
Respiratory
Appendix 5 – Deal type definitions
Appendix 6 – Further reading on dealmaking
About Wildwood Ventures
Current Partnering
Current Agreements
Recent report titles from Current Partnering
Table of figures
Figure 1: Therapeutic antibody definitions
Figure 2: Antibody partnering since 2016
Figure 3: Active antibody dealmaking activity since 2016
Figure 4: Antibody partnering by deal type since 2016
Figure 5: Antibody partnering by disease type since 2016
Figure 6: Antibody deals with a headline value
Figure 7: Antibody deals with an upfront value
Figure 8: Antibody deals with a milestone value
Figure 9: Antibody deals with a royalty rate value
Figure 10: Top antibody deals by value since 2016
Figure 11: Most active antibody dealmakers since 2016
Pricing options
- $3,995: single-user
- $5,745: multi-user
- $10,995: single site license
- $17,995: global site license
A full explanation of license type definitions can be found here.
Our guarantee
Price promise
We guarantee our prices are competitive. If you find the same report advertised at a lower price within 7 days of purchase, we will refund the difference.
Delivery Deadline
We guarantee that the report will be sent within the specified delivery times. In the unlikely case of a delay we may offer a partial refund as compensation. (Terms may apply)
Latest report
If an update is published within 30 days of your purchase, you will receive it absolutely free of charge.
Serious Security
We take your data and security seriously. See our privacy policy for details of how we manage your data.
All card payments are processed by SagePay.
Sales Support
If you have any questions about your report or are unhappy with the quality, we will do our best to resolve your query. Contact us direct.
- Total Trust
Current Partnering is part of Wildwood Ventures Ltd., based in York, United Kingdom. We have been trading successfully online since 2009 and work with some of the most famous brands in the business. We carefully select our partners to ensure that the publications meet expectations of demanding customers.
3D Medicines, 3rd People’s Hospital of Shenzhen, 3SBio, 4C Biomed, 4D Pharma, 9 Meters Biopharma, 10X Genomics, 23andMe, A*STAR Agency for Science, Technology and Research, A*STAR Bioprocessing Technology Institute, A*STAR Singapore Immunology Network, Aarhus University, Aarhus University Hospital, Aarvik Therapeutics, Abbvie, Abcam, AbCellera Biologics, AbCheck, AbClon, Abcuro, Abdul Latif Jameel Health, Ab E Discovery, Abeome, Abilita Bio, Ab Initio, ABL Bio, Ablexis, Ablynx, AbMed, Abmuno Therapeutics, Abound Bio, Aboundbio, Abpro, AbSci, Absolute Antibody, Ab Studio, AbTis, Abveris, Abzena, Accelerate Diagnostics, Accord Healthcare, Aceno Biotherapeutics, Acerta Pharma, Achaogen, Acticor Biotech, Actinium Pharmaceuticals, Active Motif, Actuate Therapeutics, Adagene, Adagio Therapeutics, AdAlta, Adaptate Biotherapeutics, Adaptimmune, Adaptive Biotechnologies, Adcendo, Adcentrx Therapeutics, ADC Therapeutics, Adimab, Adium Pharma, Adlai Nortye, Adnab, Aduro BioTech, Advanced Biological Laboratories, Advanced BioScience Laboratories, Advanced Proteome Therapeutics, Advanz Pharma, Advaxis, Aeglea BioTherapeutics, Aevi Genomic Medicine, AffaMed Therapeutics, Affibody, Affilogic, Affimed Therapeutics, Affinita Biotech, Affinity Biosciences, AGC Biologics, Agenus Bio, AgomAb Therapeutics, AgonOx, Aimed Bio, AIM ImmunoTech, AIMM Therapeutics, Aimmune Therapeutics, Ainnocence, Ajinomoto, Ajinomoto Bio-Pharma Services, Akadeum Life Sciences, Akeso Biopharma, Alamar Biosciences, Alchemab, Alder Biopharmaceuticals, Alector, Alexion Pharmaceuticals, Alfasigma, AlivaMab Discovery Services, Allakos, Allele Biotechnology and Pharmaceuticals, Allergan, Alligator Bioscience, Allinaire Therapeutic, Allogene Therapeutics, Alloy Therapeutics, Almac Group, Almirall, Alopexx, Alphamab Biopharmaceuticals, Alphamab Oncology, Alpine Immune Sciences, Alvogen, Alvotech, ALX Oncology, Alytas Therapeutics, Alzheimer's Drug Discovery Foundation, Amagma Therapeutics, Ambrx, AmerisourceBergen, Amgen, AmMax Bio, Amneal Pharmaceuticals, Amolyt Pharma, Amplyx Pharmaceuticals, Angiex, Angios, Annogen, ANP Technologies, Antengene, Anthos Therapeutics, Antidote Therapeutics, Antigen Express, Antikor Biopharma, Antitope, Aperion Biologics, Apexigen, Apollo Therapeutics, Applied BioMath, AprilBio, APRINOIA Therapeutics, Aptevo Therapeutics, Aqualung Therapeutics, Aquila BioMedical, Aravive Biologics, Arch Oncology, Arcus Biosciences, Ardeagen, argenx, Aridis Pharmaceuticals, Arizona State University, Array Biopharma, ArriVent Biopharma, Arsanis Biosciences, Arsenal Biosciences, Artisan Bio, Artizan Biosciences, ARTMS Product, Aruvant Sciences, Ascenion, Ascentage Pharma, Ascletis, Asher Biotherapeutics, Asieris MediTech, Aslan Pharma, Astellas Pharma, Astellas Pharma US, Astex Pharmaceuticals, AstraZeneca, Asylia Therapeutics, Asymchem Laboratories, Atara Biotherapeutics, Atbtherapeutics, aTen Therapeutics, Athenex, Atlab Pharma, Atlante Biotech, Atlas Antibodies, Atlas Venture, Atonco, ATP, Atreca, Attralus, ATUM, aTyr Pharma, Augmenta, Aulos Bioscience, AusHealth, Avacta, Avalo Therapeutics, AvantGen, Avantor, AVEO Oncology, Avid Bioservices, Avidity Biosciences, Avillion, Avrobio, Axantia, Bach Biosciences, Back-A-Line, Baili Biopharmaceutical, Banner Alzheimer's Institute, Basilea Pharmaceutica, Batavia Biosciences, Bausch & Lomb, Bavarian Nordic, Baxalta, Bayer, BB100, Beam Therapeutics, BeiGene, Beijing Defengrei Biotechnology, Beijing InnoCare Pharma, Beijing Tianshi Tongda Pharmaceuticals Technology, BerGenBio, Berkeley Lights, Beroni Group, Bethyl Laboratories, Betta Pharmaceuticals, Bhami Research, BHR Pharma, BigHat Biosciences, Bill and Melinda Gates Foundation, Binex, Bio-Manguinhos/Fiocruz, Bio-Techne, Bio-Thera Solutions, BioArctic Neuroscience, biOasis Technologies, BioAtla, Biocare Medical, BioCheck, Biocon, Biocytogen, Biodesix, BioDuro, Bioeq IP, Biogen, BioGenes, BioInvent, BioLegend, BiolineRX, Biolojic Design, bioLytical Laboratories, BioMarker Strategies, Biomedical Advanced Research and Development Authority, BioMed X Innovation Center, Biomm, Biomunex Pharmaceuticals, Bioncotech Therapeutics, Biond Biologics, BiondVax, BioNova Pharmaceuticals, BioNTech, BioRap Technologies, BiosanaPharma, Biosion, Biositu Pharmaceutical Technology, BioStrand, Biotem, Biothera Pharmaceuticals, Biotheus, Biotools, BioVectra, Bioventix, BioXcel, BiVictriX Therapeutics, BJ Bioscience, Blackstone, BliNK Biomedical, Bliss Biopharmaceutical, Bluebird Bio, BlueJay Therapeutics, Boehringer Ingelheim, Bolt Biotherapeutics, Boston Immune Technologies and Therapeutics, Boston Pharmaceuticals, Bpifrance, BriaCell Therapeutics, BrickBio, BridgeBio Pharma, Brigham and Women's Hospital, BrighGene Biomedical, Bright Peak Therapeutics, Brii Biosciences, Bristol-Myers Squibb, Broadwing Bio, Byondis, C-Bridge Capital, Caelum Biosciences, Caerus Discovery, Califia Pharma, California Institute for Biomedical Research, California Institute for Regenerative Medicine, Calithera Biosciences, Calixar, Calviri, Calypso Biotech, Canadian Institutes of Health Research, Cancer Australia, Cancer Focus Fund, Cancer Prevention and Research Institute of Texas, Cancer Research UK, CanCure, Candel Therapeutics, Cantargia, Caprisa, CARB-X, CardiNor, Care Access Research, CareDx, Carina Biotech, Caris Life Sciences, CARsgen, Carterra, Cartexell, CASI Pharmaceuticals, Catalent, CBT Pharmaceuticals, CDI Laboratories, CDR-Life, Cedars-Sinai Medical Center, Celdara Medical, Celgene, Celiac Disease Foundation, Cellectis, Cellerant Therapeutics, Cell Signaling Technology, Celltech, Celltrion, Celsius Therapeutics, Celularity, Cend Therapeutics, Cenexi, Centers for Disease Control and Prevention, Centre for Drug Research and Development (CDRD), Centre For The Commercialization Of Antibodies And Biologics, Centre Leon Berard, CG Oncology, Champions Oncology, Charles River Laboratories, Checkmate Pharmaceuticals, Checkpoint Therapeutics, Chi-Med, Chiesi Farmaceutici, Children's Hospital Boston, Chime Biologics, China Resources Pharmaceutical Commercial Group International Trading, Chinese Academy of Sciences, Chiome Bioscience, Chipscreen NewWay Biosciences, Chong Kun Dang, Chromotek, Chugai Pharmaceutical, Cidara Therapeutics, Cilag AG, Cipla, City of Hope, City of Hope Comprehensive Cancer Center, ClinicalRM, Clinical Trial and Consulting Services, Clinica Universidad Navarra, Clinigen, Clovis Oncology, CMAB Biopharma, CMC Biologics, CM Life Sciences, Coeptis Pharmaceuticals, Coherus Biosciences, Cold Genesys, Columbia University, Compass Therapeutics, Complement Pharma, Complix, Compugen, Conagen, Confo Therapeutics, Context Therapeutics, Convergent Therapeutics, CORAT Therapeutics, Corbus Pharmaceuticals, Corvidia Therapeutics, Corvus Pharmaceuticals, Covalab, Creative Biolabs, Creoptix, Crescendo Biologics, Cristal Therapeutics, Cromos Pharma, Crossbeta Biosciences, Crown Bioscience, CR Pharma, CRS Bio, CSL, CSL Behring, CSPC Megalith Biopharmaceutical, CSPC Pharmaceutical Group, CStone Pharmaceuticals, CtM Biotech, CTTQ-Akeso Biomed, Cue Biopharma, Cullinan Oncology, Curant Health, Curative Biotechnology, Cure Duchenne, CureVac, Curia, Curis, Cyon Therapeutics, Cytodyn, CytomX Therapeutics, Cytovation, CYTOVIA Therapeutics, Daiichi Sankyo, Dana-Farber Cancer Institute, Debiopharm, deCODE Genetics, DeepCDR Biologics, Defense Advanced Research Projects Agency, Defense Health Agency (US), Denali Therapeutics, Department of Defence, Department of Defense, Department of Health and Human Services, Dermapharm, Dermira, Diagnostic International Distribution, Diaprost, DiNonA, DiosCURE Therapeutics, Disc Medicine, Distributed Bio, Dong-A ST, DotBio, Dr. Falk Pharma, Dr. Reddy's Laboratories, Dragonfly Therapeutics, Dragon Sail Pharmaceutical, Dren Bio, DRI Capital, DualityBio, Dualogics, Duke-NUS Graduate Medical School Singapore, Duke University, Dyadic International, E25Bio, EA Pharma, eFFECTOR Therapeutics, eGenesis, EirGenix, Eisai, Elanco, Eledon Pharmaceuticals, Elektrofi, Elevation Oncology, Eleven Biotherapeutics, Elicio Therapeutics, Eli Lilly, Elpiscience, ElsaLys Biotech, Elthera, EluSys Therapeutics, Emergence Therapeutics, Emergent BioSolutions, Emory University, Empirico, Endocyte, enGene, Enlivex, ENPICOM, Enthera, Enumeral Biomedical, Enzene Biosciences, Enzolytics, Epicypher, EpimAb Biotherapeutics, EpiThany, Epivax, Epsilogen, EQRx, Equillium, Erasca, Erasmus University Medical Center, EsoCap, Essex Bio-Technology, ES Therapeutics, Ethris, Eucodis Bioscience, Eucure Biopharma, Eureka Eurostars, Eureka Therapeutics, Eurofarma, Eurofins Discovery, Eurofins Scientific, European Commission, European Union, European Union Regional Development Fund, EUSA Pharma, Eutilex, Evaxion Biotech, Everest Medicines, Eversana, Evitria, Evopoint Biosciences, Evotec, EVQLV, ExCEEd Orphan, Excellmab, Exelixis, Experimental Therapeutics Centre of Singapore, Eyam Vaccines and Immunotherapeutics, F-Star, F-Star Therapeutics, FairJourney Biologics, Fannin, FarmaMondo Group, Faron Pharmaceuticals, FatiAbGen, Femtogenix, Ferring Pharmaceuticals, FIT Biotech, Five Prime Therapeutics, Flame Biosciences, Florida International University, Flow Eighteen38, Fluidigm, FLX Bio, Food and Drug Administration (FDA), Formosa Pharmaceuticals, Forty Seven, Fosun Kite Biotechnology, Fosun Pharmaceutical, Foundery Innovations, Fred Hutchinson Cancer Research Center, Fresenius Kabi Pharmaceuticals, Friends of FSH Research, Frontage Clinical Services, Frontier Biotech, Fuhong Hanlin, Fujifilm Kyowa Kirin Biologics, Fuji Pharma, Fundacion Medina, Fusion Pharmaceuticals, Galapagos, Galaxy Biotech, Galderma, Galecto, GamaMabs Pharma, Genagon Therapeutics, Genechem, GeneData, Geneious Biologics, Genentech, GeneQuantum Healthcare, Generation Biotech, GeNeuro, Genexine, GenFleet Therapeutics, Genmab, Gennao Bio, Genome and Company, Genome BC, Genome Canada, Genor Biopharma, Genovac, Genprex, GenScript Biotech, GenScript ProBio, Genten Therapeutics, Genuv, George Mason University, Georgetown University, GeoVax, German Cancer Research Center, Gigagen, Gilead Sciences, Ginkgo BioWorks, GlaxoSmithKline, Glenmark Pharmaceuticals, Global Blood Therapeutics, Global Health Innovative Technology Fund (GHIT), Global Virus Network, Glycotope Biotechnology, GlycoT Therapeutics, Glythera, Glytherix, Goldfinch Bio, Good Therapeutics, Goodwin Biotechnology, Gossamer Bio, GO Therapeutics, Government of Canada, Government of Hong Kong, Government of Singapore, Gradalis, Granite Bio, Grey Wolf Therapeutics, Grid Therapeutics, Grifols, Gritstone Bio, GTP Technology, Guangzhou Fanen Biotechnology, Guardant Health, H-CYTE, H-Immune, H3 Biomedicine, Hadasit Bioholdings, HaemaLogiX, Hainan Sinotau Pharmaceutical, Halix, Halozyme Therapeutics, HanAll Pharmaceuticals, Hangzhou Zhongmei Huadong Pharmaceutical, Hanmi Pharmaceutical, Harbour Antibodies, Harbour Biomed, Harpoon Therapeutics, Harvard Pilgrim Health Care, Harvest Capital Strategies, Healthcare Royalty Partners, Hebrew University of Jerusalem, Heidelberg Pharma, Helix BioPharma, Hemogenyx, Henlius Biotech, HiberCell, HIBio, HiFiBio, Highlight Therapeutics, High Line Bio, Hikma Pharmaceuticals, Hisun BioRay, Hoffmann La Roche, Hong Kong University of Science & Technology, Hookipa Pharma, Hope Medicine, Horizon Discovery, Horizon Therapeutics, Huadong Medicine, Hualan Genetic, Hubrecht Institute, Humabs BioMed, Humanigen, Hummingbird Bioscience, Hutchison MediPharma, Huyabio International, I-mab, i2 Pharmaceuticals, iBio, Icahn School of Medicine at Mount Sinai, IcanoMAB, Ichnos Sciences, Ichor Medical Systems, Iconic Therapeutics, Icosagen Group, IDBiologics, iDD Biotech, iGEM, IGM Biosciences, Igyxos, Iksuda Therapeutics, Ildong Pharmaceutical, ImaginAb, Imbrium Therapeutics, ImCheck Therapeutics, ImClone Systems, Immatics Biotechnologies, Immedica, Immix Biopharma, Immorna, Immune-Onc Therapeutics, Immune Biosolutions, ImmuneCyte Life Sciences, ImmuneOncia Therapeutics, Immune Pharmaceuticals, ImmuNext, Immunitas Therapeutics, ImmunoBiochem, ImmunoBrain Checkpoint, ImmunoChina Pharmaceuticals, Immunocore, ImmunoGen, Immunome, Immunomedics, Immunomic Therapeutics, ImmunoPrecise Antibodies, ImmunoQure, Immunovaccine, Immutep, IMPACT Therapeutics, Imugene, IMV, Incyte, InDevR, Indiana University, Indian Institute of Science Education and Research, Indivumed, Infex Therapeutics, Infinity Pharmaceuticals, InflamaCORE, InflaRx, Inhalon Biopharma, Inhibrx, Initium Therapeutics, Inmagene Biopharmaceuticals, Innate Pharma, Innosuisse, Innovate UK, Innovative Targeting Solutions, Innovent Biologics, Inotrem, Inovio, Inovio Pharmaceuticals, Inserm Transfert, Inspirna, Institut Bergonie, Institute for Basic Science, Institute for Bioscience and Biotechnology Research, Institute of Cancer Research, Institut Gustave Roussy, Institut Pasteur, Institut Pasteur of Shanghai at the Chinese Academy of Sciences, Intarcia Therapeutics, Intas Pharmaceuticals, Integral Molecular, Integrated BioTherapeutics, Intellia Therapeutics, INTELLiSTEM, Intensity Therapeutics, International AIDS Vaccine Initiative, International Consortium on Anti-Virals, IntoCell, Intract Pharma, Intrexon, Invenra, Invetx, InxMed, IO Biotech, Ionova, IONTAS, Iovance Biotherapeutics, iProgen Biotech, Ipsen, IRBM, ISA Pharmaceuticals, Isogenica, IsoTherapeutics, Isotopia Molecular Imaging, Israeli National Authority for Technological Innovation, Israel Institute for Biological Research, Italian Association for the Study of Pancreas, iTeos Therapeutics, Ixaka, Ix Therapeutics, Izana Bioscience, Jacobio Pharmaceuticals, Jacobson Pharma, Janssen Biotech, Janssen Pharmaceuticals, Janssen Research & Development, Janssen Sciences, Jasper Therapeutics, Jazz Pharmaceuticals, JHL Biotech, Jiangsu Alphamab, Jiangsu Chia Tai Tianqing Pharmaceutical, Jiangsu Hansoh Pharmaceutical, Jiangsu Hengrui Medicine, Jiangsu Hengrui Pharmaceuticals, Jiangsu Qyun Bio-Pharmaceutical, Jiangsu QYuns Therapeutics, JMT-Bio, Johns Hopkins University, Johnson & Johnson, Johnson Matthey, JOINN Laboratories, Jounce Therapeutics, Juno Therapeutics, Junshi Biosciences, Just Biotherapeutics, Juvenile Diabetes Research Foundation, JW Therapeutics, Kadmon Pharmaceuticals, KAHR Medical, Kairos Therapeutics, Kaken Pharmaceutical, Kalbe Genexine Biologics, KangaBio, Karolinska Institute, KBI BioPharma, KBio, Kelun-Biotech Biopharmaceutical, Kennedy Institute of Rheumatology, Keymed Biosciences, Kiadis Pharma, Kimberly-Clark, Kindred Bio, Kineta, Kings College London, Kiniksa Pharmaceuticals, Kintor, Kite Pharma, Kitov Pharma, Kleo Pharmaceuticals, Kodiak Sciences, Kolltan Pharmaceuticals, KPM Tech, Kurma Life Sciences Partners, Kymab, Kyma Therapeutics, Kyowa Hakko Kirin, Kyowa Hakko Kirin Pharmaceuticals, Kyttaro, LabCentral, LabGenius, Laboratoires Thea, Laboratorios Liomont, Laekna, La Jolla Institute for Allergy & Immunology, LakePharma, LamKap Bio Group, LaNova Medicines, Lantern Pharma, Lantheus Holding, Lassen Therapeutics, Lava Therapeutics, Leads Biolabs, Leap Therapeutics, Lee's Pharmaceutical, Lee Moffitt Cancer Center, LegoChem Biosciences, Leica Biosystems, Leicester University, Leinco Technologies, LEO Pharma, Lepu Biopharma, Les Laboratoires Servier, Leukemia & Lymphoma Society, LeukoCom, LG Life Sciences, Libbs Farmaceutica, Libera Bio, LiberoThera, LifeArc, LifeMax Laboratories, Ligand Pharmaceuticals, Light Chain Bioscience, LimmaTech Biologics, Linnaeus Therapeutics, Liverpool School of Tropical Medicine, Livzon Mabpharm, Lobesity Pharma, Lonza, Loxo Oncology, Lumos Pharma, Lunaphore, Lundbeck, Lung Cancer Research Foundation, Lupagen, Lupus Therapeutics, Luye Pharma Group, Lyvgen Biopharma, Mab-Venture Biopharma, MAB Discovery, Mabion, Mablink Bioscience, MabQuest, MAbSilico, mAbsolve, Mabspace Bioscience, MabVax Therapeutics, mAbXience, Mabylon, Macrogenics, Macrostruct Holding & Consulting, Magenta Therapeutics, MAIA Biotechnology, Mammoth Biosciences, Manhattan BioSolutions, Mapp Biopharmaceutical, Maryland Technology Development Corporation, Massachusetts General Hospital, Massachusetts Institute of Technology, MassBiologics, Matrix Medical Network, Maverick Therapeutics, Max-Planck, Maxion Therapeutics, Mayo Clinic, Maze Therapeutics, McMaster University, MD Anderson Cancer Center, Medac, Medgenics, MediaPharma, Mediar Therapeutics, Medical Research Council, Medical Research Futures Fund, Medicenna Therapeutics, Medicines Discovery Catapult, Medigen Biotechnology, Medimabs, MedImmune, Mediolanum, Medison Pharma, Medivir, MedPacto, Meiji Seika, Memorial Sloan Kettering Cancer Center, Memo Therapeutics, Merck and Co, Merck Animal Health, Merck KGaA, Merck Sharpe & Dohme, Mereo BioPharma, Merrimack Pharmaceuticals, Mersana Therapeutics, Merus, Michael J Fox Foundation, MicroCoat Biotechnologie, Millennium, MilliporeSigma, miRagen Therapeutics, miRecule, Mitra Biotech, Mitsubishi Tanabe Pharma, Moderna, ModiQuest Research, Molcure, Moleculin Biotech, MolMed, Mologen, Momenta Pharmaceuticals, Monopar Therapeutics, MoonLake Immunotherapeutics, Morphogenesis, MorphoSys, Morphotek, Mount Sinai Health System, Mount Sinai Medical Center, MSD, Multitude Therapeutics, Mundipharma, Muscular Dystrophy Association, Mustang Bio, Mycenax Biotech, Mylan Laboratories, Mylan Pharmaceuticals, Mymee, Myriad Genetics, Mythic Therapeutics, myTomorrows, Nabriva Therapeutics, Nagoya University Graduate School of Medicine, Nanocarry Therapeutics, NanoCellect Biomedica, NanoMab Technology, NanoString Technologies, NaNotics, NantBioScience, Nantes University, NantKwest, Nanyang Technological University, Nascent Biotech, National Cancer Institute, National Center for Advancing Translational Sciences (NCATS), National Center for Tumor Diseases, National Centre for Research and Development, National Comprehensive Cancer Network (NCCN), National Eye Institute, National Heart, Lung and Blood Institute, National Institute for Bioprocessing Research and Training, National Institute of Allergy and Infectious Diseases, National Institute of Diabetes and Digestive and Kidney Diseases, National Institute of General Medical Sciences, National Institute of Neurological Disorders and Stroke, National Institute of Standards and Technology, National Institute on Aging, National Institutes of Biomedical Innovation, Health and Nutrition, National Institutes of Health, National Research Council Canada, National Research Council of Canada, National University Cancer Institute, Natrix Separations, Nautilus Biotech, Navigo Proteins, Navrogen, NBE Therapeutics, Nectin Therapeutics, Nektar Therapeutics, Nelum Pharma, NeoBiotechnologies, NeoImmuneTech, Neoleukin Therapeutics, Neon Therapeutics, Neovii Pharmaceuticals, NeoX Biotech, Nerviano Medical Sciences, NETRIS Pharma, Neuracle Genetics, Neuramedy, Neurimmune Therapeutics, Neuroblastoma and Medulloblastoma Translational Research, Newsummit Biopharma, New York Blood Center, Neximmune, NextCure, Nexvet, NGM Biopharmaceuticals, Nihon Medi-Physics, NJ Bio, NJCTTQ, Nkarta Therapeutics, NKGen Biotech, NKMax America, NMI Natural and Medical Sciences Institute, Nona Biosciences, Nordic Nanovector, Nordic Society of Gynaecological Oncology, Noria Therapeutics, Normunity, Northern Biologics, NorthStar Medical Radioisotopes, Northway Biotechpharma, Northwestern University, Nouscom, Novadiscovery, NovalGen, NovaRock Biotherapeutics, Novartis, Novasep, Novelogics Biotechnology, Novelty Nobility, NovImmune, NovoCodex, Novocure, Novogene, Novo Nordisk, Noxopharm, Noxxon Pharma, NuclixBio, Numab, Nykode Therapeutics, OBI Pharma, Oblique Therapeutics, OcellO, Oculis, Odeon Therapeutics, Oligomerix, Olivia Newton-John Cancer Research Institute, Ology Bioservices, Olympic Protein Technologies, Omeros, OMERS, OmniAb, OncoC4, OncoCare Therapeutics, OncoImmune, Oncologie, Oncolytics Biotech, OncoMed Pharmaceuticals, OncoQuest, OncoResponse, OncoSec Medical, OncoTAb, OncoVent, OncoVerity, Oncternal Therapeutics, Oncurious, OnCusp Therapeutics, OncXerna Therapeutics, Ono Pharmaceutical, Onward Therapeutics, OpenEye Scientific Software, Optimeos Life Sciences, Oragenics, Orano Med, Ordaos Bio, Oregon Health Sciences University, Orient EuroPharma, Orion, Orsini Healthcare Specialty Pharmacy, OSE Immunotherapeutics, Ossianix, Otsuka, Outlook Therapeutics, Ovensa, Overland ADCT BioPharma, Overland Pharmaceuticals, Oxford BioTherapeutics, Oxford Genetics, Oxford Immunotec, Oxgene, Palisade Bio, Pall Corporation, Panacea Pharmaceuticals, Pandion Therapeutics, Pangu BioPharma, Panorama Research, Paragon Therapeutics, Parexel, Parexel Biotech, Pascal Biosciences, Patheon, Paul Scherrer Institute, PCI Pharma Services, PDS Biotechnology, Pelican Therapeutics, Peptron, Peregrine Pharmaceuticals, Perrigo, Personal Genome Diagnostics, Personalis, Pfizer, Phanes Therapeutics, PharmAbcine, PharmaMar, Pharmapark, Pharmsynthez, PhaseBio Pharmaceuticals, pH Pharma, Pieris Pharmaceuticals, Pierre Fabre, Pionyr Immunotherapeutics, Piramal, PlantForm, PlantPraxis Biotecnologia, PMV Pharma, Pneuma Respiratory, POINT Biopharma, Polpharma, Portage Biotech, Portal Instruments, Poseida Therapeutics, Precision BioSciences, Prellis Biologics, Pressure BioSciences, Prestige BioPharma, Prince William Science Accelerator, ProBioGen, Procarta Biosystems, ProciseDx, ProfoundBio, PROGEN Biotechnik, Progenetics, Progenics Pharmaceuticals, Prokaryotics, Promega, Prometheus Biosciences, ProMIS Neurosciences, Protelica, Proteona, Prothena Biosciences, ProtoKinetix, Provention Bio, PT Etana Biotechnologies, PULSALYS, Pure Biologics, PureTech Health, Purolite, Pyxis Oncology, Q32 Bio, QBiotics, Qiagen, Qilu Pharmaceutical, Quadira Biosciences, Quanterix, Quantum Leap Health Care Collaborative, Queensland Institute of Medical Research (QIMR), Quellis Biosciences, Quell Therapeutics, Quest PharmaTech, Qurient, R-Pharm, Radboud University Nijmegen Medical Centre, Radiopharm Theranostics, Rakuten Medical, Rallybio, Ramot at Tel Aviv University, Rani Therapeutics, Redwood Bioscience, RefleXion Medical, Regeneron Pharmaceuticals, Regenxbio, Regnum, Releviate Therapeutics, REMD Biotherapeutics, RemeGen, Renato Dulbecco Foundation, RenBio, Rentschler Biotechnologie, Repligen, Replimune, Resonant Therapeutics, Retrogenix, Revelar Biotherapeutics, Revitope Oncology, Rexahn Pharmaceuticals, Reyon Pharmaceuticals, Rezolute, Ridgeback Biotherapeutics, RNAGene, Roche, Rockefeller University, Rocket Pharmaceuticals, Roivant Sciences, Roswell Park Cancer Institute, Royalty Pharma, RQ Biotechnology, RubrYc Therapeutics, Rxilient Biotech, Ryvu Therapeutics, SAB Biotherapeutics, SAB Therapeutics, Saccharo, Sahlgrenska University Hospital, Sairopa, Salipro Biotech, Samsung Bioepis, Samsung Biologics, Samyang Biopharmaceuticals, San Diego Biomedical Research Institute, Sandoz, Sanford Burnham Institute, Sanofi, Sanofi-Aventis, Sanofi-Pasteur, Sanofi US Services, Sanquin Blood Supply Foundation, Sanyou Biopharmaceuticals, Sarah Cannon Research Institute, Sartorius Stedim Biotech, SATT Sud-Est, Saudi Pharmaceutical Industries & Medical Appliances Corporation (SPIMACO), SaudiVax, Scandion Oncology, Scholar Rock, Schrodinger, SciClone Pharmaceuticals, SciCrunch, Scientist.com, Scil Proteins, SciNeuro Pharmaceuticals, Scripps Research Institute, Seagen, Sea Lane Biotechnologies, Seattle Children's Hospital, Seattle Genetics, Seismic Bio, Selagine, Selecxine, Selexis, SELLAS Life Sciences Group, Sema4, Sengenics, Sensei Biotherapeutics, Seranova Bio, SerImmune, Serono, Serum Institute of India, Seven and Eight Biopharmaceuticals, SevenScore Pharmaceuticals, SFJ Pharmaceuticals, Shandong Boan Biological Technology, Shandong Fontacea Pharmaceutical, Shanghai Affinity Biopharmaceutical, Shanghai ChemPartner, Shanghai Miracogen, Shanghai ZhenGe Biotechnology, Sharp HealthCare, Shenogen Pharma, Shenzhen Arimab Biopharmaceuticals, Shenzhen Chipscreen Biosciences, Shenzhen Hepalink Pharmaceutical, Shionogi, Shire Laboratories, Shire Pharmaceuticals, Siamab Therapeutics, Siemens Healthineers, SillaJen, Silverback Therapeutics, Simcere Pharmaceuticals, Simcha Therapeutics, Simon Fraser University, Singlomics Biopharmaceuticals, Sino Biological, Sinopharm, Sirnaomics, Siteman Cancer Center, Skysong Innovations, SmartPharm Therapeutics, SomaLogic, Sonnet BioTherapeutics, Sorrento Therapeutics, Sosei Heptares, SOTIO, Spanish National Research Council, Specialised Therapeutics, Specialized Medical Services-oncology, Specifica, Spotlight Innovation, Spring Bank Pharmaceuticals, SpringWorks Therapeutics, STADA Arzneimittel, Staidson (Beijing) BioPharmaceuticals, Stanford University, Starpharma, Staten Biotechnology, STC Biologics, STCube, Steinbeis Centre for Biopolymer Analysis and Biomedical Mass Spectrometry, Stony Brook University, Strata Oncology, Sud Investments, Summit Therapeutics, Sun Pharmaceutical, SunRock Biopharma, Surface Oncology, Surrozen, Sutro Biopharma, Swedish Orphan, Swedish Orphan Biovitrum, Swiss Commission for Technology and Innovation, Swiss Federal Funding Programme, Swiss Federal Institute of Technology ETH Zurich, Swixx Biopharma, Symphogen, Synaffix, Syndax Pharmaceuticals, Syneos Health, Synergys Biotherapeutics, Syngene International, Synimmune, Synlogic, Synthon, Syracuse Biopharma, Syracuse University, Syros Pharmaceuticals, Systimmune, T-Cure Bioscience, Tachyon Therapeutics, Taiho, Takeda Pharmaceutical, Talem Therapeutics, Tallac Therapeutics, Tanabe Research Laboratories, Targovax, TARIS Biomedical, Tasly Pharmaceuticals, Tavotek Biotherapeutics, TCR2 Therapeutics, Technical University of Denmark (DTU), Tegmine Therapeutics, Teijin, Tekon Biotech, Telcon RF Pharmaceuticals, Telix Pharmaceuticals, Tempest Therapeutics, Tempus, TeneoBio, TeneoOne, Teon Therapeutics, Tesaro, Tessa Therapeutics, Tetragenetics, Teva Pharmaceutical Industries, TFF Pharmaceuticals, TG Therapeutics, The International AIDS Vaccine Initiative, Theragen, Theramex, Theranyx, Therapharm, Theratechnologies, Thermo Fisher Scientific, ThromboGenics, Tianjin University, TILT Biotherapeutics, Tiziana Life Sciences, Tizona Therapeutics, Tmunity Therapeutics, TONIX Pharmaceuticals, TopAlliance Biosciences, Topas Therapeutics, Torch Biosciences, Toregem BioPharma, Torque Therapeutics, TOT BIOPHARM, Totient, Touchlight, TRACON Pharmaceuticals, Transcenta, Transgene, TransPerfect Life Sciences, TransThera, Tri-Institutional Therapeutics Discovery Institute, TrialSpark, Trianni, Trieza Therapeutics, TRIGR Therapeutics, Trinomab Biotech, Trio Pharmaceuticals, Triumvira Immunologics, TrueBinding, TSB Therapeutics, Tsinghua University, Tubulis, TuHURA Biopharma, Turgut Ilaclari, Turning Point Therapeutics, Twist Bioscience, UbiVac, Ubix Therapeutics, UCB, Ultragenyx Pharmaceuticals, Uman Diagnostics, UnitedHealth, Universite Claude Bernard Lyon, University College London, University Gottingen, University Hospital Bonn, University Hospital Heidelberg, University of Alabama at Birmingham, University of Basel, University of Bergen, University of Birmingham, University of Bonn, University of British Columbia, University of California, San Diego, University of California Los Angeles, University of California Riverside, University of California San Francisco, University of Edinburgh, University of Florida, University of Heidelberg, University of Illinois at Chicago, University of Kansas, University of Maryland School of Medicine, University of Melbourne, University of Natural Resources and Life Sciences, University of New Mexico, University of North Texas Health Science Center, University of Oxford, University of Pennsylvania, University of Southampton, University of Texas, University of Tubingen, University of Turku, University of Washington, University of Wisconsin Carbone Cancer Center (UWCCC), University of Zurich, University Paris Diderot, Upadia, Uppsala University, UroGen Pharma, US Army Medical Research and Material Command, US Army Medical Research Institute of Infectious Diseases, US Government, Utrecht University, Vaccinex, ValenzaBio, Vanderbilt University, Vaximm, VBI Vaccines, Vcell Healthcare, Vect-Horus, VectorY Therapeutics, Vedanta Biosciences, Velabs Therapeutics, Veloxis Pharmaceuticals, venBio, Verastem, Vera Therapeutics, Veraxa Biotech, Verseau Therapeutics, Vertex Pharmaceuticals, Vetigenics, Vetter, Viela Bio, Vincera Pharma, Vinnova, ViralClear Pharmaceuticals, Vir Biotechnology, Viroclinics Biosciences, Visterra, Vitaeris, Vitesse Biologics, Vizient, Vor Biopharma, Voyager Therapeutics, VU University Amsterdam, Vyera Pharmaceuticals, VyGen-Bio, Vyriad, Wacker Biotech, Walgreens, Washington University in St Louis, Wellmarker Bio, WEP Clinical, Werewolf Therapeutics, Wilex, WindMIL Therapeutics, Wisconsin Alumni Research Foundation, Wistar Institute, World Health Organization, WuXi Biologics, Wuxi Shuangliang Biotechnology, Wuxi STA, WuXi XDC, XBiotech, Xbrane Bioscience, xCella Biosciences, Xencor, XERIS Pharmaceuticals, Xiamen Biotime Biotechnology, Xilio Therapeutics, XNK Therapeutics, Xoma, Xyphos Biosciences, Y-Biologics, Y-mAbs Therapeutics, Yale University, Yas Holding, Yissum Research Development, Ymmunobio, Yufan Biotechnologies, YUMAB, ZabBio, ZAI Laboratory, Zebra Biologics, Zenas BioPharma, Zenoaq, Zhejiang Bossan Pharmaceutical, Zhejiang Hisun Pharmaceutical, Zhejiang Huahai Pharmaceutical, Zoetis, Zumutor Biologics, Zurich School of Applied Sciences, Zydus Cadila, Zymeworks, ZyVersa Therapeutics
Current Partnering reports provide insight into the trends and terms of partnering deals in the global life sciences sector.
Current Partnering reports are updated every six months to ensure the user has access to the latest announcements and trends in the topic focus of the report.
Current Partnering analysts review the deal data to provide an overview and analysis of deal trends, including example deals and terms.
Current Partnering reports source deal data from our proprietary deals and alliances database, Current Agreements. The database is updated daily by our analysts with new deals as they are announced globally by the company’s party to the deal. In addition, deal records are updated with new data as it becomes available.
The data in the Current Agreements deals and alliances database is obtained from secondary sources such as publicly available industry sources including press releases, company presentations, investor presentations, company SEC filings, other company filings, company websites, conference presentations. Sources are identified to allow for user verification.
Current Partnering provides comprehensive coverage of the following partnering or deal types:
• Asset purchase
• Assignment
• Co-development
• Co-market
• Co-promotion
• Collaborative R&D
• Contract service
• CRADA
• Cross-licensing
• Development
• Distribution
• Equity purchase
• Evaluation
• Grant
• Joint venture
• Licensing
• Loan
• Manufacturing
• Marketing
• Option
• Promotion
• Research
• Royalty financing
• Settlement
• Spin out
• Sub license
• Supply
• Termination
• Warrant
Every deal record is fully categorized and includes the following data, where available:
• Industry sector
• Therapy areas
• Technology type
• Deal components
• Financial terms
• Stage of development
• Exclusivity
• Asset type
• Geographic focus
• Excluded geography
• Company press release
• SEC filing data including contract document
All financial amounts are converted to US$ using the exchange rate available on the date of deal announcement, enabling direct comparison of deal terms across international territories.
Financial data and contract documents displayed in deal records is obtained from public sources, where disclosed by the parties to the deal.
